Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment

R.J. Boosman*, T.P.C. Dorlo, N. de Rouw, J.A. Burgers, A.M.C. Dingemans, M.M. van den Heuvel, L.E.L. Hendriks, B. Biesma, J.G.J.V. Aerts, S. Croes, R.H.J. Mathijssen, A.D.R. Huitema, R. Ter Heine

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)1576-1584
Number of pages9
JournalInternational Journal of Cancer
Volume149
Issue number8
DOIs
Publication statusPublished - 15 Oct 2021

Keywords

  • estimated glomerular filtration rate
  • neutropenia
  • non-small cell lung cancer
  • pemetrexed
  • prophylactic strategies
  • CONTINUAL REASSESSMENT METHOD
  • PHASE-I EVALUATION
  • MULTITARGETED ANTIFOLATE
  • NEUTROPENIA
  • LY231514
  • CANCER
  • MODEL
  • INHIBITOR
  • ACID

Cite this